Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging - PubMed (original) (raw)

Comparative Study

Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging

Deng-Shun Wang et al. J Neuropathol Exp Neurol. 2005 May.

Abstract

Although evidence suggests that extensive cortical beta-amyloid (Abeta) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Abeta, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Abeta1-40 and Abeta1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and alpha-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Abeta1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Abeta degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.

PubMed Disclaimer

Cited by

Isolation Housing Exacerbates Alzheimer's Disease-Like Pathophysiology in Aged APP/PS1 Mice.
Huang H, Wang L, Cao M, Marshall C, Gao J, Xiao N, Hu G, Xiao M. Huang H, et al. Int J Neuropsychopharmacol. 2015 Jan 7;18(7):pyu116. doi: 10.1093/ijnp/pyu116. Int J Neuropsychopharmacol. 2015. PMID: 25568286 Free PMC article.
Increased levels of Stress-inducible phosphoprotein-1 accelerates amyloid-β deposition in a mouse model of Alzheimer's disease.
Lackie RE, Marques-Lopes J, Ostapchenko VG, Good S, Choy WY, van Oosten-Hawle P, Pasternak SH, Prado VF, Prado MAM. Lackie RE, et al. Acta Neuropathol Commun. 2020 Aug 21;8(1):143. doi: 10.1186/s40478-020-01013-5. Acta Neuropathol Commun. 2020. PMID: 32825842 Free PMC article.
Deletion of UCP1 in Tg2576 Mice Increases Body Temperature and Exacerbates Alzheimer's Disease-Related Pathologies.
Jung CG, Yamashita H, Kato R, Zhou C, Matsushita H, Takeuchi T, Abdelhamid M, Chen Y, Michikawa M. Jung CG, et al. Int J Mol Sci. 2023 Feb 1;24(3):2741. doi: 10.3390/ijms24032741. Int J Mol Sci. 2023. PMID: 36769062 Free PMC article.
Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance.
Marr RA, Hafez DM. Marr RA, et al. Front Aging Neurosci. 2014 Aug 13;6:187. doi: 10.3389/fnagi.2014.00187. eCollection 2014. Front Aging Neurosci. 2014. PMID: 25165447 Free PMC article. Review.
The Study of Postmortem Human Synaptosomes for Understanding Alzheimer's Disease and Other Neurological Disorders: A Review.
Jhou JF, Tai HC. Jhou JF, et al. Neurol Ther. 2017 Jul;6(Suppl 1):57-68. doi: 10.1007/s40120-017-0070-z. Epub 2017 Jul 21. Neurol Ther. 2017. PMID: 28733958 Free PMC article. Review.

Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging - PubMed (original) (raw)